	Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol Chen Q, Wu J, Cai Q. PMID: 41712034 [PubMed - as supplied by publisher]
	Thrombosis-related gene signature predicts prostate cancer recurrence and immune therapy: insights from retrospective cohorts, bioinformatics, and experimental validation. Inflamm Res Luo Y, Chen P, Situ M, Zhuang W, Huang J, Wang B, Wang Q, Peng S, Huang H. PMID: 41711904 [PubMed - indexed for MEDLINE]
	[The OPTIMUM trial: microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis]. Urologie Cash H, Borkowetz A. PMID: 41711899 [PubMed - as supplied by publisher]
	MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study. Abdom Radiol (NY) Bai X, Xu H, Zhou S, Jia T, Yi S, Zhao H, Xie L, Liu B, Liu X, Liu H, Mu X, Zhang M, Zhao J, Ye H, Ma X, Wang H. PMID: 41711878 [PubMed - as supplied by publisher]
	Thyroid cartilage resection surgery for metastases of clear cell renal cell carcinoma: case report and literature review. Einstein (Sao Paulo) Lisboa LZ, Cunha GBD, Pinheiro MLP, Haddad L, Ceccon FP. PMID: 41711787 [PubMed - indexed for MEDLINE]
	Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects. Nanoscale Zhang P, Xiong W, Wang K, Zhao X, Liu X, Huang M. PMID: 41711555 [PubMed - as supplied by publisher]
	Impact of Bariatric Surgery on Prostate Cancer Screening Rate. J Am Coll Surg Brown N, Alexander AJ, Horns JJ, Hardikar S, Playdon M, Das R, Driggs N, Paudel N, Ibele A. PMID: 41711321 [PubMed - indexed for MEDLINE]
	A Unified Machine Learning Model for Relapse Prediction in Clinical Stage I Testicular Cancer. Andrology Wagner T, Marandi RZ, Lauritsen J, Murray DD, Bandak M, Grønkær Toft B, Berney D, Daugaard G. PMID: 41711113 [PubMed - as supplied by publisher]
	Correction to "Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial". Cancer PMID: 41711095 [PubMed - in process]
	Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer. Front Microbiol Liu X, Chen Z, Lu Y, Wu Y, Huang Y, Zhang Y, Li M, Feng N. PMID: 41710924 [PubMed]
	In vitro cytotoxicity of medicinal plants used in prostate cancer management in Africa: a systematic review. Trop Med Health Bwesigye T, Nerima B, Kyambadde J, Mulindwa J, Byarugaba I, Sekandi P. PMID: 41709315 [PubMed - as supplied by publisher]
	Development and Validation of an AI-Assisted Predictive Model Integrating R2* Mapping and Clinical Indicators for Clinically Significant Prostate Cancer. Cancer Med Li X, Shi Y, Fang J, Zhang R, He X, Ai G. PMID: 41709083 [PubMed - indexed for MEDLINE]
	Physical activity at baseline and risk of prostate cancer grade reclassification on active surveillance: results from a prospective cohort study. Prostate Cancer Prostatic Dis Higgins MI, Su ZT, Mamawala M, Jing Y, Landis PK, Alshak MN, Grutman AJ, Rivera Lopez CA, Pavlovich CP, Trock BJ. PMID: 41708991 [PubMed - as supplied by publisher]
	Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-GuÃ©rin (BCG) in BCG-naÃ¯ve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)]. Eur Urol Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M. PMID: 41708452 [PubMed - as supplied by publisher]
	MRI-Based Habitat Radiomics for Predicting Postoperative Recurrence in Nonmetastatic Clear Cell Renal Cell Carcinoma. Acad Radiol Yi S, Jia T, Bai X, Kang H, Zhao J, Liu B, Li C, Wen X, Xu H, Ning X, Liu H, Cui M, Zhou S, Ma Y, Xie L, Zhao H, Ma X, Wang H. PMID: 41708388 [PubMed - as supplied by publisher]
	Risk Factor of Persistent Hypotension Associated with 5-Aminolevulinic Acid: A Single-Institution Retrospective Study. Biol Pharm Bull Okada N, Kimura H, Ozaki M, Tamura M, Ochi F, Sasaki T, Takimoto T, Kitahara T. PMID: 41708090 [PubMed - indexed for MEDLINE]
	To Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database. Int J Urol Kobayashi S, Shiota M, Onozawa M, Taguchi S, Yamamoto Y, Sakamoto S, Kawai T, Nakagawa T, Hinotsu S, Eto M, Kume H, Japan Study Group of Prostate Cancer (J. PMID: 41708074 [PubMed - indexed for MEDLINE]
	Molecular insights for the tumor suppressor role of SPOP in prostate cancer. Biochim Biophys Acta Rev Cancer Yan P, Xue X, Hou T, Wang J, Jiang W, Wang Z, Inuzuka H, Wei W. PMID: 41707797 [PubMed - as supplied by publisher]
	Optimising on-treatment review schedules: A narrative review of acute toxicities in ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) for localised prostate cancer. Radiography (Lond) McKenna G, Flood T. PMID: 41707610 [PubMed - as supplied by publisher]
	Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A, KEYNOTE-905/EV-303 Investigators. PMID: 41707170 [PubMed - as supplied by publisher]

Articles 1 - 20 / 176125

Page 1 of 8807



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy